December 11, 2020
ARLINGTON, Va. — HDA President and CEO Chester “Chip” Davis, Jr., released the following statement on the U.S. Food and Drug Administration’s (FDA) decision to grant Emergency Use Authorization of the first COVID-19 vaccine, manufactured by Pfizer and BioNTech.
“Today’s decision by the FDA marks a historic turning point in the fight against this global pandemic. While we acknowledge the hard work and determination that got us to this moment, we also recognize that this is just the first step as the federal and state governments partner with the healthcare supply chain to mobilize a logistics undertaking unlike any this country has ever seen.
“As the public and private sectors join in this highly coordinated effort, HDA pharmaceutical distributors — a critical link between manufacturers and provider points of administration — stand ready to help turn vaccines into vaccinations, employing their expertise to ensure newly approved COVID-19 vaccines are distributed safely, efficiently and quickly to the American public.”
The Healthcare Distribution Alliance (HDA) represents primary pharmaceutical distributors — the vital link between the nation’s pharmaceutical manufacturers and pharmacies, hospitals, long-term care facilities, clinics and others nationwide. Since 1876, HDA has helped members navigate regulations and innovations to get the right medicines to the right patients at the right time, safely and efficiently. The HDA Research Foundation, HDA’s non-profit charitable foundation, serves the healthcare industry by providing research and education focused on priority healthcare supply chain issues.